Patents Issued in February 15, 2024
  • Publication number: 20240050464
    Abstract: In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example pruritus, a disorder related to elevated serum cholesterol concentration, or reducing elevated low-density lipoprotein cholesterol (LDL) concentration in a patient.
    Type: Application
    Filed: September 25, 2023
    Publication date: February 15, 2024
    Applicant: Viscera Labs, Inc.
    Inventors: Stephen TAGLIENTI, Steven L. PETRUCCELLI
  • Publication number: 20240050465
    Abstract: Hydrogen water for inhibition of alcoholic hepatopathy, to be mixed with ethanol, has a dissolved hydrogen concentration of 550 ppb to 5600 ppb. The concentration of the ethanol in the hydrogen water when mixed with the ethanol is 1% to 4%.
    Type: Application
    Filed: January 11, 2022
    Publication date: February 15, 2024
    Inventor: Taichi HARA
  • Publication number: 20240050466
    Abstract: A nutritional supplement composition formulated having antioxidant and anti-inflammatory nutrients reduces cellular biomarkers of DNA damage and improves cellular regenerative capacity.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 15, 2024
    Inventors: Caroline Felicity BULL, Michael FENECH, Scott William POXON, Bernardus Jan-Willem VAN KLINKEN
  • Publication number: 20240050467
    Abstract: A system and method of use for an operational halotherapy device and red light device in an enclosed space. The halotherapy and red light system generally comprise a machine disposed in the enclosed space that disperses salt particles into the air, and includes a red light device that emits red light waves. The combination of both devices produces a refractory phenomenon when the red light waves make contact with the salt particles dispersed in the air to cause a plethora of multi-dimensional dispersions of light waves. Moreover, every time a salt particle makes contact with a red light wave, a portion of the wave light is absorbed by the particle and its temperature increases, lessening the moisture in the particle. The lessening of moisture in the particle dries the particle further, which enhances the therapeutic properties of the inhalable salt particle.
    Type: Application
    Filed: October 17, 2023
    Publication date: February 15, 2024
    Inventors: John J. Brier, JR., Edwin A. Weihenmayer, IV
  • Publication number: 20240050468
    Abstract: A formulation in gel form comprising erbium borate nanoparticles, at least one surfactant and at least one gelling agent with carrier gel properties for use in prevention and treatment of wound scars is provided.
    Type: Application
    Filed: November 9, 2021
    Publication date: February 15, 2024
    Applicant: YEDITEPE UNIVERSITESI
    Inventors: Fikrettin SAHIN, Erhan AYSAN, Pakize Neslihan TASLI, Oguz Kaan KIRBAS, Batuhan Turhan BOZKURT, Berna BULBUL
  • Publication number: 20240050469
    Abstract: Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 15, 2024
    Applicant: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: RAPHAEL G. RAPTIS, INDRANIL CHAKRABORTY, SHAMBHU KANDEL
  • Publication number: 20240050470
    Abstract: A method to inhibit reperfusion injury to a tissue that has experienced ischemia comprising treating the ischemic tissue with an antioxidant solution prior to or in conjunction with reperfusion of blood into the ischemic tissue pursuant to artery bypass surgery, angioplasty or in conjunction with an angiogram. The antioxidant solution is comprised of water, dissolved salts of calcium, potassium, magnesium, sodium, one or more buffers, L-Arginine, glucose, glutathione, and ascorbic acid and wherein the solution is ionically and pH balanced to a physiologic pH, preferably 7.2-7.4.
    Type: Application
    Filed: October 18, 2023
    Publication date: February 15, 2024
    Inventors: Tracy Goeken, Bernard Winkler
  • Publication number: 20240050471
    Abstract: The present disclosure provides for methods of activating an immune cell in a subject by administering to the subject a CYR61 activating agent, as well as methods of treating ocular neovascularization in a subject by administering a CYR61 activating agent to an immune cell to form a treated immune cell and administering the treated immune cell to the subject.
    Type: Application
    Filed: August 11, 2023
    Publication date: February 15, 2024
    Applicant: Washington University
    Inventors: Rajendra Apte, Joseph Lin, Philip Ruzycki
  • Publication number: 20240050472
    Abstract: Provided are an anti-Claudin 18.2 antigen-binding fragment or antibody, and the use thereof. CDR3 of a heavy chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 3. CDR3 of a light chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 6. The provided antigen-binding fragment and anti-Claudin 18.2 antibody can specifically bind to a variety of sources of Claudin 18.2 proteins, have no binding effect on other proteins, and have a high specificity. In addition, a chimeric antigen receptor and a CAR-T cell prepared by means of the antibody have obvious cytotoxicity on cells stably expressing the Claudin 18.2 protein.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 15, 2024
    Applicant: GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD
    Inventors: Min Luo, Guangchao Li, Wen Ding, Zhao Zhou, Xuejun Wang
  • Publication number: 20240050473
    Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) and chimeric antigen receptors comprising GCC antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules are provided herein.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Inventors: Gary SHAPIRO, Johara CHOUITAR, Xingyue HE, Mei Rosa NG
  • Publication number: 20240050474
    Abstract: Provided are engineered cells (such as stem cells or T cells) that have a surface molecule comprising a membrane-tethered binding moiety that binds to a T cell surface antigen (such as CCR5, CD4 or CXCR4) or a HIV antigen, or a membrane tethered inhibitory moiety that inhibits the membrane fusion of HIV (such as C34). Also provided are methods of making and using these engineered cells.
    Type: Application
    Filed: February 8, 2022
    Publication date: February 15, 2024
    Inventors: Ming Zeng, Weiming Wang
  • Publication number: 20240050475
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds to human PRDX4 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides said pharmaceutical composition for use in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining in a sample obtained from said human subject whether PRDX4 is present on the cell surface of cells comprised by said sample. Additionally, an antibody which binds to human PRDX4 present on the cell surface of a target cell is provided.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 15, 2024
    Inventor: Reinhard Zeidler
  • Publication number: 20240050476
    Abstract: The invention relates to methods for treatment of cancers utilizing a combination of a deoxyribonuclease enzyme and adoptive cell immunotherapy comprising cells expressing a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In particular embodiments, the deoxyribonuclease enzyme can be given parenterally or encoded by a vector or secreted by a cell comprising TCR or CAR.
    Type: Application
    Filed: January 7, 2022
    Publication date: February 15, 2024
    Applicant: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS, Alexey Vyacheslavovich STEPANOV
  • Publication number: 20240050477
    Abstract: The present invention provides a lipid nanoparticle and the like containing a pH-sensitive cationic lipid represented by formula (1) (in formula (1), R1 and R2 are each independently a straight-chain C10-14 alkyl group, a straight-chain C10-20 alkenyl group having one or two unsaturated bonds, or —CH(R5)(R6)(where R5 and R6 are each independently a straight-chain C5-10 alkyl group); p represents an integer of 3-8; and R3 and R4 are each independently a methyl group or an ethyl group].
    Type: Application
    Filed: February 17, 2022
    Publication date: February 15, 2024
    Applicant: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Takashi Nakamura, Hideyoshi Harashima, Yusuke Sato, Koharu Yamada, Taisei Nakade
  • Publication number: 20240050478
    Abstract: The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4 (+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.
    Type: Application
    Filed: August 24, 2023
    Publication date: February 15, 2024
    Inventors: Bo Kyung Min, Hana Choi, Yu Kyeong Hwang
  • Publication number: 20240050479
    Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
    Type: Application
    Filed: October 5, 2023
    Publication date: February 15, 2024
    Inventors: Martin E. Sanders, Vidyasagar Vuligonda
  • Publication number: 20240050480
    Abstract: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
    Type: Application
    Filed: October 26, 2023
    Publication date: February 15, 2024
    Inventor: Michael Har-Noy
  • Publication number: 20240050481
    Abstract: The present disclosure includes a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a blister-derived cell of a patient with dystrophic epidermolysis bullosa that is genetically modified to produce type VII collagen.
    Type: Application
    Filed: July 21, 2021
    Publication date: February 15, 2024
    Applicants: OSAKA UNIVERSITY, STEMRIM INC.
    Inventors: Katsuto TAMAI, Yasushi KIKUCHI, Tomoki TAMAKOSHI, Takehiko YAMAZAKI
  • Publication number: 20240050482
    Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
    Type: Application
    Filed: January 26, 2023
    Publication date: February 15, 2024
    Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
  • Publication number: 20240050483
    Abstract: In various aspects and embodiments, this disclosure provides methods for generating hematopoietic stem cells (HSCs), as well as compositions comprising the same, and methods of treating disease. The disclosure provides methods for preparing endothelial cells from pluripotent stem cells by expression (e.g., overexpression) of E26 transformation-specific variant 2 (ETV2) transcription factor. HSCs are then generated from the endothelial cells using mechanical, biochemical, pharmacological and/or genetic stimulation.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 15, 2024
    Inventor: Dhvanit SHAH
  • Publication number: 20240050484
    Abstract: The present invention relates to a cell gel preparation, which is used for treating and/or preventing acute or chronic osteoarthritis and/or symptoms thereof by means of intra-articular injection, wherein the preparation comprises a nucleic acid hydrogel loading mesenchymal stem cells. The present invention further relates to a method for treating or preventing acute and chronic osteoarthrosis and associated symptoms caused by inflammation (especially osteoarticular pain and activity or function loss) by means of using the cell gel preparation, and a method for reducing the shear damage on cells in a shear environment by means of using the nucleic acid hydrogel.
    Type: Application
    Filed: October 8, 2021
    Publication date: February 15, 2024
    Inventors: Dongsheng Liu, Jiakuo Yu, Bo Yang, Xin Yan, Yujie Li, Bini Zhou, Xin Li
  • Publication number: 20240050485
    Abstract: Disclosed are means, treatments and compositions of matter useful for treatment of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse reduction in lung function associated with COPD. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of pulmonary regeneration directly or indirectly.
    Type: Application
    Filed: August 14, 2023
    Publication date: February 15, 2024
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, Feng LIN, James VELTMEYER
  • Publication number: 20240050486
    Abstract: The present disclosure provides methods for generating cortical excitatory neurons, cortical excitatory neurons generated by such methods, and composition comprising such cells. The present disclosure also provides uses of the cortical excitatory neurons and composition comprising thereof for preventing and/or treating neurodegenerative disorders.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 15, 2024
    Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases
    Inventors: Lorenz Studer, Gabriele CICERI
  • Publication number: 20240050487
    Abstract: The present disclosure relates to an immuno-potentiating composition, more specifically to a composition containing an enzymatic extract of deer antler with excellent NK cell activity as an active ingredient, which exhibits immuno-potentiating effect by proliferating immune cells and particularly enhancing NK cell activity and, as such, can be used as a food composition and further as a health functional food or pharmaceutical composition for immuno-potentiation.
    Type: Application
    Filed: December 29, 2021
    Publication date: February 15, 2024
    Applicant: YUHAN CARE CO., LTD.
    Inventors: Jongsoo KANG, Kyung In CHUNG, Il PARK, Hyun Je PARK, Aeri SONG, Semi EOM, Hye Jin JEON, Sin Hwa BAEK
  • Publication number: 20240050488
    Abstract: A method of treating diaper rash in a subject is provided. A method of treating athlete's foot in a subject is provided. A method of treating contact dermatitis in a subject is provided. A method of treating perspiration and body odor in a subject is provided. The method comprises administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the diaper rash, athlete's foot, contact dermatitis, or perspiration and body odor. Related preparations, kits, and devices are also provided.
    Type: Application
    Filed: October 26, 2023
    Publication date: February 15, 2024
    Inventors: Todd Krueger, David R. Whitlock, Lauren Nicole Ambrogio, Larry Weiss
  • Publication number: 20240050489
    Abstract: The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.
    Type: Application
    Filed: October 12, 2023
    Publication date: February 15, 2024
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Matthew J. HAMILTON, Alexander KHORUTS, Michael J. SADOWSKY, Christopher M. STALEY
  • Publication number: 20240050490
    Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
    Type: Application
    Filed: July 11, 2023
    Publication date: February 15, 2024
    Applicant: Seres Therapeutics, Inc.
    Inventors: Gregory MCKENZIE, Mary-Jane LOMBARDO MCKENZIE, David N. COOK, Marin VULIC, Geoffrey VON MALTZAHN, Brian GOODMAN, John Grant AUNINS, Matthew R. HENN, David Arthur BERRY, Jonathan WINKLER
  • Publication number: 20240050491
    Abstract: A method of generating an antimicrobial agent is disclosed. The method comprises: (a) culturing Bacillus cells in a medium under conditions effective to allow secretion of at least one antimicrobial agent into the medium; and (b) purifying the at least one antimicrobial agent from the medium to generate a purified preparation comprising the at least one antimicrobial agent. Uses of the antimicrobial agents secreted from the Bacillus cells are also disclosed.
    Type: Application
    Filed: September 14, 2023
    Publication date: February 15, 2024
    Applicant: The state of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization
    Inventors: Moshe SHEMESH, Yulia KROUPITSKI, Shlomo SELA
  • Publication number: 20240050492
    Abstract: The present disclosure describes probiotic compositions comprising Emergencia timonensis and methods for using probiotic compositions comprising Emergencia timonensis to reducing TMA and/or TMAO levels in subjects in need thereof.
    Type: Application
    Filed: August 15, 2023
    Publication date: February 15, 2024
    Applicant: Oregon State University
    Inventors: Veronika Kivenson, Stephen J. Giovannoni
  • Publication number: 20240050493
    Abstract: The present invention relates to a composition comprising Pediococcus pentosaceus LB606R, deposited under the assession number DSM 33730; Lactiplantibacillus plantarum, LB679R, deposited under the assession number DSM 33731; or a combination hereof.
    Type: Application
    Filed: December 29, 2021
    Publication date: February 15, 2024
    Applicant: Lactobio A/S
    Inventors: Charlotte VEDEL, Katja BILLEKOP OLSEN, Jens Edward TESDORPF, Søren KJÆRULFF
  • Publication number: 20240050494
    Abstract: Disclosed herein are methods and compositions useful for the treatment of subjects suffering from Prader-Willi Syndrome (PWS). The methods include administering compositions comprising probiotics, such as Lactobacillus reuteri (L. reuteri) and Bifidobacterium animalis subsp. lactis (B. lactis) to subjects in need thereof.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 15, 2024
    Inventor: Xue-Jun Kong
  • Publication number: 20240050495
    Abstract: Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.
    Type: Application
    Filed: June 30, 2022
    Publication date: February 15, 2024
    Applicant: GI BIOME INC.
    Inventors: Bo Gie YANG, Myung Ho JANG, Han Sung LEE
  • Publication number: 20240050496
    Abstract: A probiotic composition comprising Bacillus amyloliquefaciens, Enterococcus faecalis, Lactobacillus salivarius, Lactobacillus johnsonii, Lactobacillus gallinarum and Lactobacillus crispatus is provided. The probiotic composition stimulates the immune response of chickens without negatively affecting growth performance. The probiotic composition can be added to poultry feed to improve the health and performance of chickens, and can be used as a replacement for antibiotic supplementation.
    Type: Application
    Filed: October 19, 2023
    Publication date: February 15, 2024
    Inventors: Deon Pieter Neveling, Leon Milner Theodore Dicks
  • Publication number: 20240050497
    Abstract: Use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 15, 2024
    Inventors: Simone Domenico GUGLIELMETTI, Ruggero ROSSI, Walter FIORE, Andrea BIFFI
  • Publication number: 20240050498
    Abstract: The formation method was revealed of a bacteriophage synergistic composition intended to prevent and combat infections of livestock, including but not limited to poultry, with pathogenic bacteria strains sensitive to the phages.
    Type: Application
    Filed: June 28, 2021
    Publication date: February 15, 2024
    Applicant: Proteon Pharmaceuticals S.A.
    Inventors: Jaroslaw DASTYCH, Ewelina A. WÓJCIK, Agnieszka MASZEWSKA, Malgorzata STANCZYK, Anna PEKALA, Edyta SMIGIELSKA, Ewelina WOJDA, Joanna KAZIMIERCZAK, Arkadiusz GUZI?SKI, Justyna ANDRYSIAK, Paulina WIGNER
  • Publication number: 20240050499
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Application
    Filed: October 31, 2023
    Publication date: February 15, 2024
    Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Eun Kyoung OH, Soo Youn JUN, Sang Hyeon KANG
  • Publication number: 20240050500
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Application
    Filed: October 31, 2023
    Publication date: February 15, 2024
    Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Eun Kyoung OH, Geun Woo LEE, Soo Youn JUN, Sang Hyeon KANG
  • Publication number: 20240050501
    Abstract: The invention discloses a method for forming a fungi fermentation product containing N-acetylglucosamine. The fungi fermentation product containing N-acetylglucosamine can convert cancer cells into normal cells through a mesenchymal epithelial transition mechanism. The method uses fungi as a starting material which together with a Cordyceps-related fungus is fermented to form a fermentation product which induces a mesenchymal epithelial transition to convert cancer cells into normal cells. The fungi cell wall contains chitin. The fermentation liquid is produced by fermentation of Cordyceps with chitin as the substrate. The main product is N-acetylglucosamine confirmed by an HPLC analysis. According to the experimental data, the fermentation product of N-acetylglucosamine converts cancer cells into epithelial cells that contain E-cadherin and has a square shape.
    Type: Application
    Filed: March 22, 2023
    Publication date: February 15, 2024
    Inventor: Kun-Lin Yang
  • Publication number: 20240050502
    Abstract: Disclosed are compositions containing two purified Amanita muscaria compounds chosen from the following: ibotenic acid, muscimol, muscazone, stizolobic acid, stizolobinic acid, muscarine, muscamfin, muscaflavin, betalamic acid, muscapurpurin, muscaaurins, acetylcholine, atropine, hyoscyamine, L-3,4-dihydroxyphenylalanine, phallolysin, scopolamine, fucomannogalactan, B(1?6)-branched (1?3)-?-d-glucan, amatoxins, phallotoxins, or the salts of these Amanita muscaria compounds. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Pharmaceutical formulations further containing a therapeutically effective amount of a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene a disclosed. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 15, 2024
    Inventor: Andrew R. CHADEAYNE
  • Publication number: 20240050503
    Abstract: A method can relate to the use of flower essence-containing medicaments, particularly those that are useful for the alleviation of stress. More particularly, though not exclusively, a method can relate to topical applications including creams, such as facial and body cream, oils, spritzers and toners and serums, for oral and/or external application, that are useful for the alleviation of stress. Compositions provide a combination of advantageous properties of a cosmetic composition including one or more of Appearance, Odour, Ease of Application, Ease of Absorbency, Absorbency time, Greasiness (lower score if greasier), Irritation, Skin, Feel (softness) and Skin Moisturisation. Compositions can include one or more plant stem cell extracts in combination with one or more flower essences. A composition can preferably include extracts from Fitzroya cupressoide.
    Type: Application
    Filed: August 3, 2022
    Publication date: February 15, 2024
    Inventors: Clare G. Harvey, Dori Naerbo
  • Publication number: 20240050504
    Abstract: The present invention relates to the preparation technical field of traditional Chinese medicine and more particularly, to a traditional Chinese medicine eye drops and the preparation method thereof. The traditional Chinese medicine components of the traditional Chinese medicine eye drops provided by the embodiments of the invention comprise: ginseng radix et rhizoma of 5-10 wt %, scrophulariae radix of 15-20 wt %, xanthii fructus of 5-10 wt %, bovis calculus sativus of 5-10 wt %, carthami flos of 5-10 wt %, borneolum of 5-10 wt %, senecionis scandentis herba of 25-35 wt %, fibraureae caulis of 5-15 wt % and motherwort fruit of 5-10 wt %.
    Type: Application
    Filed: August 11, 2022
    Publication date: February 15, 2024
    Inventor: See Tung Kwan
  • Publication number: 20240050505
    Abstract: Disclosed is a method for treating skin. The method can include topically applying to skin in need thereof a composition comprising effective amounts of Arctium lappa root extract and Epilobium angustifolium extract to reduce expression of a pro-inflammatory cytokine of IL-8, IL-2, or TNF-? in the skin.
    Type: Application
    Filed: March 20, 2023
    Publication date: February 15, 2024
    Inventors: Michelle HINES, Tiffany CARLE
  • Publication number: 20240050506
    Abstract: A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension. Method for reducing surface tension in a steviol glycoside solution includes contacting a steviol glycoside and a surface tension reducing compound.
    Type: Application
    Filed: June 2, 2023
    Publication date: February 15, 2024
    Applicant: CARGILL, INCORPORATED
    Inventors: Dan S. GASPARD, Adam John STEINBACH, Adam T. ZARTH
  • Publication number: 20240050507
    Abstract: A method for preparing a Plectranthus amboinicus (PA) extract, the method comprising extracting an above-ground part of Plectranthus amboinicus with an extracting solution that comprises a solvent having a suitable polarity index, filtrating and concentration the extract thus produced, and subject the concentrated extract to a chromatographic separation process using a hydrophobic interaction chromatography resin to produce the PA extract.
    Type: Application
    Filed: October 27, 2023
    Publication date: February 15, 2024
    Applicant: Oneness Biotech Co., Ltd.
    Inventors: Yueh-Ju Wang, Kung-Ming Lu
  • Publication number: 20240050508
    Abstract: A pharmaceutical product of the present invention contains plant parts obtained from the neem tree Azadirachta indica or active ingredients derived from such plant parts for use in treating, preventing and/or alleviating symptoms of restless legs syndrome.
    Type: Application
    Filed: October 27, 2023
    Publication date: February 15, 2024
    Inventor: Martin VORDERWÜLBECKE
  • Publication number: 20240050509
    Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
    Type: Application
    Filed: February 21, 2023
    Publication date: February 15, 2024
    Applicant: KUALITY HERBCEUTICS LLC
    Inventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo
  • Publication number: 20240050510
    Abstract: The present invention concerns methods and compositions employing a combination of Uncaria rhynchophylla (UR) herb and an antidepressant or anxiolytic drug therapy for treating or preventing anxiety, stress, depression, and/or symptoms thereof, wherein the combined administration of UR and the drug elicit a fast on-set response in the subject.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Applicant: THE OPEN UNIVERSITY
    Inventor: Ravid DORON
  • Publication number: 20240050511
    Abstract: Methods for promoting intestinal health of a subject in need thereof and for enhancing antioxidation in a subject in a subject in need thereof are provided. The methods include administering to the subject a prebiotic composition, which includes grape ferment, lactitol, and fructooligosaccharide. The weight ratio of the grape ferment, the lactitol, and the fructooligosaccharide falls within the range of 1-2:1-2:1-2. The grape ferment is obtained by fermenting grape extract with Saccharomyces cerevisiae and Streptococcus thermophilus.
    Type: Application
    Filed: October 27, 2023
    Publication date: February 15, 2024
    Inventors: YUNG-HSIANG LIN, CHU-HAN HUANG
  • Publication number: 20240050512
    Abstract: The present invention relates to a composition comprising one or more of clove oil, eucalyptus oil, basil oil, ginger oil, an extract or component of any of these, or a combination thereof, and to a buffer composition having a pH of from 6.7 to 7.9 at a temperature of 37° C., both for use in the treatment, prophylactic treatment or amelioration of an airborne viral infection, or for use in reducing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in the subject. The present invention also relates to an aqueous composition either comprising a buffer and an essential oil with antiviral, antibacterial or antifungal activity; or comprising a buffer, hydrogen carbonate ions, and zinc ions; or comprising a buffer, hydrogen carbonate ions, and transferrin and/or iron ions. The present invention also relates to methods of preparing the compositions, and to concentrates of the compositions.
    Type: Application
    Filed: November 25, 2021
    Publication date: February 15, 2024
    Inventors: Mohammed Abid Masood, Rakesh Uppal, Angela Russell, Laurence Silpa
  • Publication number: 20240050513
    Abstract: A peptide with terminal tyrosine has an excellent effect on inhibiting protein nitration and also an excellent effect on preventing, ameliorating, or treating disease symptoms in chronic immobilization stress-induced depression/cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.
    Type: Application
    Filed: February 23, 2022
    Publication date: February 15, 2024
    Inventors: Hyun Joon KIM, Young Bum KIM, Jae Soon KANG, Soonwoong JUNG, Miyoung SONG, Ji Hyeong BAEK, Sang Won PARK, Hwajin KIM, Dae Young YOO